What a Blood NAD+ Test Can and Cannot Tell You

A blood NAD+ test measures NAD+ in blood, not in muscle or brain, and no verified source gives a normal range. Trials show NR and NMN raise blood NAD+ within about two weeks. No trial in the sources checked showed that acting on the number improves health, so for most people the test has no decision attached.

The short answer You can have a lab measure NAD+ in a blood sample, but the number describes your blood, not your muscle or brain. In trials, NR and NMN raised blood NAD+ within about two weeks, so a test can show that a precursor reached the blood. No verified source gives a normal range, and the one healthy-adult mean we found came from a single study's method. Test only if a clinician will change your care because of the result. Otherwise the number has no decision attached.

NAD+ is made from niacin, and the NIH Office of Dietary Supplements notes that more than 400 enzymes need it to run their reactions (NIH ODS, Niacin Health Professional Fact Sheet). Start with the overview of what NAD+ does and which precursors raise it if the basics are new. This page covers the question most people ask after seeing a lab report: what a blood number can and cannot tell you.

Why isn't a blood NAD+ number simple?

A lab report gives one number with a unit, and it invites a comparison with a normal range. The research has not supplied one. One side argues that repeated measurement could tune doses (Kuerec et al., 2024). The other side has no outcome trial showing that acting on the number helps. Blood is a compartment of its own, and the human studies that measured both blood and tissue did not always agree.

Here is the finding that changes how to read a result. In a 2026 study of 12 adults taking 1,200 mg a day of NR or NMN, blood NAD+ rose slowly and leveled off at about two weeks. Brain NAD+ rose measurably only after four weeks, in the same people (Berven et al., 2026). Blood and brain ran on different clocks.

Methods matter too. A 2020 study of whole blood extracted NAD+ with a hot buffered ethanol step and quantified it in triplicate (Breton et al., 2020). A 2021 method paper, tested in mice, built a mass spectrometry assay for 26 NAD-related metabolites and prepared each sample type differently (Cuny et al., 2021). A number from one method is not a benchmark for another method.

The most quoted human figure is also the least representative. A 2016 study reported that human blood NAD+ can rise as much as 2.7-fold after one oral dose of NR, but that figure came from a pilot study of one person (Trammell et al., 2016). Two of its authors list ChromaDex, a company that makes NR, as an affiliation. Read the headline number with that context.

What do the studies show?

Blood response to NR or NMN in healthy adults (Christen et al., 2026). This was a randomized, open-label, placebo-controlled study of 65 healthy adults over 14 days. It measured circulating NAD+ and whole-blood NAD+ metabolites, including an acute window after nicotinamide. NR and NMN raised circulating NAD+ by a comparable amount over 14 days, while nicotinamide acted only briefly. The limits are the open-label design, the two-week duration, and authors who list Nestlé Research and Nestlé Health Science as affiliations (PubMed).

Blood response in people with mild cognitive impairment (Martens et al., 2026). This 12-week, double-blind, randomized, placebo-controlled pilot had 42 completers, 22 on NR and 20 on placebo. It measured blood NAD+ and cognitive function, the primary outcome. Blood NAD+ roughly doubled in the NR group, and the primary cognitive outcome did not improve. The limits are the pilot size and the single 12-week window (PubMed).

Blood versus brain (Berven et al., 2026). Twelve adults, six healthy and six with Parkinson's disease, took 1,200 mg a day of NR or NMN. Blood and brain NAD+ were measured in the same people. Blood NAD+ rose slowly, plateaued at about two weeks, and fell slowly after stopping. Brain NAD+ rose measurably after four weeks, and responses varied widely between people. The limit is the design: 12 people in a phase I pharmacokinetic study shows timing, not outcomes (PubMed).

Muscle after NR (Remie et al., 2020; Dollerup et al., 2019). Remie and colleagues ran a crossover trial in 13 adults with overweight or obesity, giving 1,000 mg of NR a day for six weeks against placebo, and took muscle biopsies. Muscle NAD+ synthesis markers and metabolites rose. Dollerup and colleagues randomized 40 men with obesity and insulin resistance to 1,000 mg of NR twice daily or placebo for 12 weeks. Muscle NAD+ metabolite concentrations did not change. The two muscle results disagree, and both studies are small and in narrow populations (PubMed; PubMed).

Brain in Parkinson's disease (Brakedal et al., 2022). Thirty people with newly diagnosed, untreated Parkinson's disease took 1,000 mg of NR or placebo for 30 days in a randomized phase I trial. Cerebral NAD+, measured by phosphorus magnetic resonance spectroscopy, rose significantly but variably. The NAD+ metabolome also rose in blood cells, muscle, or both. The limits are the 30 participants and the 30-day window (PubMed).

The one case where blood worked as a marker (Pirinen et al., 2020). Patients with adult-onset mitochondrial myopathy, and matched controls, took niacin titrated to 750 to 1,000 mg a day, for 10 months in patients and 4 months in controls. Blood NAD+ rose up to eightfold, muscle NAD+ in patients reached control levels, and the authors concluded that blood analysis is useful for identifying NAD+ deficiency. This is a disease population taking niacin, not healthy adults (PubMed).

Variation within one trial (Kuerec et al., 2024). This post-hoc analysis of an 80-person NMN trial gave placebo or 300, 600, or 900 mg of NMN a day for 60 days. The change in blood NAD+ had a large coefficient of variation within each group, 29.2 to 113.3 percent, and the authors propose monitoring blood NAD+ to personalize dosing. The limits are the post-hoc design and the fact that several authors list commercial companies as affiliations (PubMed).

The broader picture (Gallagher and Emmanuel, 2026). This PRISMA-guided systematic review covered 113 preclinical and clinical studies, 33 of them human intervention studies. In humans, oral NR and NMN consistently engaged NAD+ metabolites in blood or cells. Functional, metabolic, and vascular outcomes were mixed and often null, and the authors judge clinical effectiveness to "remain inconclusive." The limit is that it is a two-author review (PubMed).

Evidence grades, outcome by outcome

Which situation are you in?

Find your row before you order anything. Dose, form, and safety for each ingredient are in the NMN monograph and the NR monograph.

A lab report with no reference range is a measurement, not an assessment. If the lab prints an interval, ask where it came from. An interval printed by a lab reflects that lab's method and sample, and the sources checked do not show it applies to anyone else. For intravenous NAD+ rather than oral precursors, the human evidence for liposomal or IV NAD+ is a separate question.

How do you read a result if you test anyway?

Ask four questions before the draw. What is measured, whole blood or plasma? What method is used? What units appear on the report? Does the report include a reference interval, and what is its source? The 2020 blood donor study and the 2021 method paper show that sample type and method change how NAD+ is extracted and measured (Breton et al., 2020; Cuny et al., 2021). Those answers decide whether two numbers can be compared at all.

Write down two dates: the time of the draw and the time of your last dose. In the 2026 trial of 65 adults, nicotinamide moved whole-blood NAD+ only briefly, while NR and NMN raised it over 14 days (Christen et al., 2026). A reading taken soon after a dose and a reading taken after two weeks answer different questions.

Repeat the test with the same lab and method, and treat any single reading as one point. The 2024 NMN analysis found coefficients of variation from 29.2 to 113.3 percent within dose groups, so one change between two draws says little about the trend (Kuerec et al., 2024). Do not compare results across labs.

If you want the human doses behind the trials, the NR and NMN dose comparison lists them. Before you buy either ingredient, the label checklist shows what to look for.

When should you ask a clinician first?

Ask a clinician before you order the test if you take prescription medicines, have a condition under care, or plan to add an NAD+ precursor to a treatment. A blood NAD+ value does not diagnose a condition in any source checked here, and it does not explain symptoms. Persistent fatigue, weakness, or changes you cannot explain are reasons to see a clinician, not reasons to order a NAD+ test.

The one setting where a blood NAD+ result identified a deficiency was a rare mitochondrial muscle disorder under specialist care (Pirinen et al., 2020). Outside that setting, the sources checked do not support using the number to decide on treatment. If side effects appear after starting either ingredient, stop and ask a clinician.

Next reads

For the wider picture, start with the overview of what NAD+ does and which precursors raise it. For the trials that raised blood NAD+ and still missed their functional targets, read the NAD+ precursor trials that found nothing. If the decision ends in a purchase, the buying guide for NMN and NR supplements compares labels and what to check before you pay.

More on NAD+ and Cellular Energy: The Complete Guide